Robust anti-SARS-CoV2 single domain antibodies cross neutralize multiple viruses.
Immunology, and Drugs
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
15 Jul 2022
15 Jul 2022
Historique:
received:
22
02
2022
revised:
08
05
2022
accepted:
02
06
2022
pubmed:
16
6
2022
medline:
16
6
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
We report robust SARS-CoV2 neutralizing sdAbs targeting the viral peptides encompassing the polybasic cleavage site (CSP) and in the receptor binding domain (RBD) of the spike (S) protein. Both the sdAbs inhibited infectivity of the CoV2 S protein expressing pseudoviruses (LV-CoV2S). Both anti-CSP and RBD intrabodies (IB) inhibited the output of LV(CoV2 S). Anti-CSP IB altered the proteolytic processing and targeted the viral S protein for degradation. Because of cross-reactive CSPs in the entry mediators, the anti-CSP sdAb neutralized
Identifiants
pubmed: 35702569
doi: 10.1016/j.isci.2022.104549
pii: S2589-0042(22)00821-5
pmc: PMC9181070
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104549Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Elife. 2020 Oct 28;9:
pubmed: 33112236
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Nat Protoc. 2012 Apr 19;7(5):935-45
pubmed: 22517260
Biomater Sci. 2020 Jul 7;8(13):3559-3573
pubmed: 32490444
Protein Expr Purif. 2017 Aug;136:39-44
pubmed: 28214589
Infect Immun. 2001 Aug;69(8):4851-7
pubmed: 11447160
N Engl J Med. 2020 Dec 31;383(27):2684-2686
pubmed: 33326716
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Toxicon. 2019 Oct 25;172:15-18
pubmed: 31689425
Clin Transl Immunology. 2019 Aug 05;8(8):e1073
pubmed: 31406574
Biomolecules. 2020 Dec 21;10(12):
pubmed: 33371447
BioDrugs. 2020 Aug;34(4):435-462
pubmed: 32301049
Cell Res. 2020 Apr;30(4):343-355
pubmed: 32231345
Virol J. 2013 Aug 26;10:266
pubmed: 23978242
J Virol. 2021 Apr 12;95(9):
pubmed: 33563656
PLoS Pathog. 2021 Jan 25;17(1):e1009246
pubmed: 33493182
Annu Rev Immunol. 2018 Apr 26;36:695-715
pubmed: 29490163
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Front Immunol. 2020 Oct 22;11:581076
pubmed: 33193385
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Cell. 2020 May 28;181(5):1004-1015.e15
pubmed: 32375025
Viruses. 2019 Sep 09;11(9):
pubmed: 31505793
Nat Rev Immunol. 2010 Jul;10(7):514-26
pubmed: 20577268
Clin Transl Immunology. 2020 Apr 26;9(4):e1126
pubmed: 32346479
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Nat Microbiol. 2021 Jul;6(7):899-909
pubmed: 33907312
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
J Transl Med. 2020 Jun 3;18(1):222
pubmed: 32493510
Nucleic Acids Res. 2020 Dec 16;48(22):12502-12522
pubmed: 33264393
ACS Nano. 2020 Aug 25;14(8):10616-10623
pubmed: 32806067
J Virol. 1981 Nov;40(2):350-7
pubmed: 6275093
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
iScience. 2020 Jun 26;23(6):101212
pubmed: 32512386
Front Immunol. 2021 Apr 12;12:630307
pubmed: 33912160
Protein Sci. 2002 Mar;11(3):500-15
pubmed: 11847273
J Exp Med. 2010 Jul 5;207(7):1485-500
pubmed: 20566717
Microb Cell Fact. 2011 Jun 09;10:44
pubmed: 21658216
Microbes Infect. 2020 Oct;22(9):400-402
pubmed: 32653475
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
EMBO J. 2020 Dec 1;39(23):e106267
pubmed: 33051876
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
PLoS Pathog. 2010 May 06;6(5):e1000882
pubmed: 20463811
J Virol. 2012 Apr;86(7):3975-84
pubmed: 22278228
PLoS Pathog. 2015 Mar 11;11(3):e1004730
pubmed: 25760441